Editas Medicine, Inc. (EDIT)
Oxford Ledge is still expanding full research coverage of EDIT. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Gene editing company developing CRISPR-based medicines, primarily for in vivo treatment of genetic diseases.
SEC filings
- 8-K Shareholder vote results 2026-06-18
- 8-K Entry into material agreement; Other material event; Financial statements and exhibits 2026-05-26
- 8-K Other material event 2026-05-26
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-05-26
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-05-14
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for EDIT. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open EDIT in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.